Table 1 Correlation of CDH1 mutation to clinicopathological features of GC

From: Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer

Clinicopathologic feature

CARIS (N = 1596)

TCGA (N = 436)

CDH1-MT (%)

CDH1-WT (%)

p

CDH1-MT (%)

CDH1-WT (%)

p

Agea

Median

57

64

<0.001b

60

68

0.01b

(15–90)

(12–94)

(41–79)

(30–90)

Female

55

64

0.002b

58.5

69

0.073

(27–90)

(12–94)

(41–78)

(34–90)

Male

59.5

64

0.051

60

67

0.065

(15–86)

(12–94)

(43–79)

(30–90)

Gender

Female

73 (12.7)

502 (87.3)

0.0035b

14 (9.0)

144 (91.0)

0.728

Male

82 (8.0)

939 (92.0)

28 (10.0)

251 (90.0)

Type

Non-GEJ

149 (12.4)

1053 (87.6)

<0.001b

-

-

-

GEJc

6 (1.5)

388 (98.5)

-

-

Lauren subtyped

Diffuse

33 (26.8)

90 (73.2)

<0.001b

18 (21.2)

67 (78.8)

<0.001b

Intestinal

1 (1.4)

72 (98.6)

9 (4.7)

181 (95.3)

Mixed or unclear

121 (8.6)

1279 (91.4)

15 (9.3)

146 (90.7)

  1. aMedian (range).
  2. bA two-sided p < 0.05 was considered statistically significant. p was calculated by chi-square test, unpaired two-tailed t-test, nonparametric test, or one-way analysis of variance separately.
  3. cGEJ gastroesophageal junction.
  4. dTCGA cohort: Diffuse subtype includes signet ring cell carcinoma; Intestinal subtype includes tubular stomach adenocarcinoma, papillary stomach adenocarcinoma, and mucinous stomach adenocarcinoma.